Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Opioid use disorder treatment: methadone, buprenorphine, naltrexone

    Opioid use disorder is a chronic, treatable condition; the FDA estimates about 4 million people in the US aged 12 or older had it in 2025.[1] Three medicines are approved - methadone, buprenorphine and naltrexone - and NIDA says they reduce the risk of overdose death, yet fewer than 1 in 5 people with the disorder receive them.[1][2] Since 2023 US clinicians no longer need a special waiver to prescribe buprenorphine, and a 2024 rule loosened methadone clinic requirements.[3][4]

    Editor reviewedStrict sourcingUpdated Explainer22 claims · 100% primaryDrugs, alcohol and addiction, Health and medicine

    Opioid use disorder (OUD) is a chronic medical condition. The FDA estimates that about 4 million people in the US aged 12 or older had it in 2025.[1] Medicines are the core of treatment, and federal rules on prescribing them changed substantially in 2023 and 2024. This page explains the options and the evidence.

    This page is general information, not medical advice, and it gives no dosing information. Decisions about medicines for opioid use disorder should be made with a qualified clinician. Never stop or change a prescribed medicine without medical advice.

    For treatment referrals in the US, call SAMHSA’s National Helpline at 1-800-662-4357 (1-800-662-HELP) or visit FindTreatment.gov. If someone may be overdosing, call 911 and give naloxone if you have it. If you or someone you know is in crisis or thinking about suicide, call or text 988.

    NIDA points people to the SAMHSA helpline and FindTreatment.gov for treatment and to 988 in a crisis.[5]

    What opioid use disorder is

    NIDA says a person is diagnosed with opioid use disorder if they meet two or more of the criteria in the DSM-5. These include using more than intended, cravings, continuing despite problems, and withdrawal when stopping.[6] WHO describes the core feature of opioid dependence as a strong internal drive to use opioids, with impaired control and continued use despite harm.[7]

    The three medicines

    MedicineHow it acts (FDA category)Where it is given in the US
    MethadoneAgonist[1]Only approved opioid treatment programs[8]
    BuprenorphinePartial agonist[1]Many doctors, nurse practitioners and physician assistants, including by telehealth[9]
    Naltrexone (extended-release)Antagonist[1]Any health care provider can prescribe it[10]

    Methadone has been used for more than 50 years. It activates the same opioid receptors as heroin and fentanyl, but more slowly, so it eases withdrawal and cravings with less intense pleasurable effects.[8] Patients usually start by attending a clinic every day or almost every day.[8]

    Buprenorphine activates opioid receptors less strongly than methadone. It comes as tablets placed under the tongue, extended-release injections, implants, and products combined with naloxone.[9] It can also be started in the emergency department after an overdose, which NIDA says can help motivate long-term treatment.[11]

    Naltrexone works only by blocking opioid receptors, so opioids no longer produce pleasure. It is available as a monthly injection.[10] Before starting it, a person usually has to stop taking opioids for 7 to 10 days.[10] Naltrexone is also approved for alcohol use disorder; see alcohol use disorder explained.[12]

    A fourth medicine, lofexidine, is approved specifically to treat withdrawal symptoms.[13]

    What the evidence shows

    NIDA says these medicines reduce the risk of overdose death and of behaviours that spread HIV and hepatitis C.[2] WHO says opioid agonist maintenance with methadone or buprenorphine has the strongest evidence of effectiveness and cost-effectiveness. WHO also lists psychosocial support and naltrexone among recommended options.[14]

    On comparisons, NIDA says methadone and buprenorphine can be equally effective at reducing opioid use and both help people stay in treatment, with methadone possibly keeping some people in treatment longer.[15] A common worry is that treatment swaps one drug for another. NIDA says that when taken as prescribed, methadone and buprenorphine do not produce the same high as illegal opioids.[16] It also says these medicines are safe and effective in pregnancy and while breastfeeding.[17]

    The gap is access. NIDA says fewer than 1 in 5 people with opioid use disorder are treated with these medicines.[2] Worldwide, WHO says fewer than 10% of people who need treatment for opioid dependence receive it.[18]

    How US rules changed in 2023 and 2024

    The end of the X-waiver. Until the end of 2022, US clinicians needed a special federal waiver under the Drug Addiction Treatment Act of 2000 to prescribe buprenorphine for OUD. The Consolidated Appropriations Act, 2023, enacted on 29 December 2022, removed that requirement immediately.[3]

    The 2024 methadone clinic rule. In February 2024, SAMHSA published a final rule updating the federal rules for opioid treatment programs (42 CFR part 8). It took effect on 2 April 2024, with compliance required by 2 October 2024.[4] Under the rule, patients can receive take-home methadone from the start of treatment if their clinician judges it appropriate. It also removed the requirement of a one-year history of opioid misuse before admission.[4] Opioid treatment programs can now start buprenorphine through telehealth without a first in-person exam, building on a flexibility first allowed during the COVID-19 emergency.[19]

    NIDA says NIDA-funded studies found that allowing more take-home methadone doses is safe and may help people stay in treatment.[20] As of June 2023, more than 2,000 opioid treatment programs were caring for more than 650,000 patients.[21]

    CDC lists better access to evidence-based treatment among the factors behind the fall in overdose deaths since 2023.[22] See the opioid overdose crisis explained, fentanyl explained and naloxone explained.

    Next in the crash course

    More in Drugs & addiction

    Questions readers ask

    What medicines treat opioid use disorder?

    The FDA groups approved medicines into three categories - an agonist (methadone), a partial agonist (buprenorphine) and an antagonist (extended-release naltrexone). NIDA adds that lofexidine is approved to ease withdrawal symptoms.[1][13]

    Do these medicines work?

    NIDA says medications for opioid use disorder reduce the risk of overdose death and of behaviours that spread HIV and hepatitis C. WHO says opioid agonist maintenance treatment with methadone or buprenorphine has the strongest evidence of effectiveness and cost-effectiveness.[2][14]

    Isn't methadone or buprenorphine just replacing one drug with another?

    NIDA says that when taken as prescribed by a person with opioid use disorder, methadone and buprenorphine do not produce the same high as illegal opioids.[16]

    Do doctors still need an X-waiver to prescribe buprenorphine?

    No. The Consolidated Appropriations Act, 2023, enacted on 29 December 2022, eliminated the DATA-2000 waiver requirement. NIDA says many doctors, nurse practitioners and physician assistants can now prescribe buprenorphine, including by telehealth.[3][9]

    Where can people get methadone?

    NIDA says that in the US methadone for opioid use disorder is available only from approved opioid treatment programs. A 2024 federal rule lets clinicians allow take-home doses from the start of treatment based on clinical judgment.[8][4]

    Is treatment safe during pregnancy?

    NIDA says medications for opioid use disorder are safe and effective during pregnancy and breastfeeding.[17]

    Sources

    · 22 claims from 6 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      The FDA calls opioid use disorder a chronic medical condition, estimates that about 4 million people in the US aged 12 or older had it in 2025, and groups approved medications into three categories - an agonist (methadone), a partial agonist (buprenorphine) and an antagonist (extended-release naltrexone). confirmedas of 2026-11-07

    2. [2]

      NIDA says medications for opioid use disorder reduce the risk of overdose death and of behaviours that spread HIV and hepatitis C, but fewer than 1 in 5 people with opioid use disorder are treated with them. confirmedas of 2026-11-07

    3. [3]

      The Consolidated Appropriations Act, 2023, enacted on 29 December 2022, eliminated the requirement for US practitioners to obtain a special DATA-2000 waiver before prescribing buprenorphine for opioid use disorder. confirmedas of 2024-02-02

    4. [4]

      A SAMHSA final rule published on 2 February 2024 updated federal opioid treatment program regulations (42 CFR part 8), effective 2 April 2024 with compliance by 2 October 2024; it lets patients receive take-home methadone from entry into treatment based on clinical judgment and removes the requirement of a one-year history of opioid misuse before admission. confirmedas of 2024-02-02

    5. [5]

      NIDA directs people seeking substance use or mental health treatment referrals to SAMHSA's National Helpline at 1-800-662-HELP (4357) or FindTreatment.gov, and people in a substance use or mental health crisis to call or text 988. confirmedas of 2026-11-07

      • Fentanyl · National Institute on Drug Abuse · Primary source · Help box, page footer (retrieved 2026-11-07)
      • Fentanyl · National Institute on Drug Abuse · Primary source · Help box, page footer (retrieved 2026-11-07)
    6. [6]

      NIDA says a person is diagnosed with opioid use disorder if they have two or more of the symptoms listed in the DSM-5, such as using more than intended, cravings, continuing despite problems, or withdrawal when stopping. confirmedas of 2026-11-07

    7. [7]

      WHO describes opioid dependence as a disorder of regulation of opioid use whose characteristic feature is a strong internal drive to use opioids, shown by impaired control, giving use priority over other activities and continuing despite harm. confirmedas of 2026-11-07

    8. [8]

      NIDA says methadone has been used for more than 50 years to treat opioid use disorder, activates opioid receptors more slowly than heroin or fentanyl and so produces less intense pleasure while reducing withdrawal and cravings, and in the US is available for this purpose only from approved opioid treatment programs, which patients usually attend daily or almost daily at first. confirmedas of 2026-11-07

    9. [9]

      NIDA says buprenorphine activates opioid receptors less than methadone, can be prescribed by many doctors, nurse practitioners and physician assistants without a specialist clinic, can be prescribed by telehealth, and comes as under-the-tongue tablets, extended-release injections, implants and combination products with naloxone. confirmedas of 2026-11-07

    10. [10]

      NIDA says naltrexone, also approved for alcohol use disorder, works only by blocking opioid receptors, is available as a monthly long-acting injection that any health care provider can prescribe, and usually requires a person to stop opioids for 7 to 10 days before starting. confirmedas of 2026-11-07

    11. [11]

      NIDA says buprenorphine treatment can be started in the emergency department after an overdose to ease withdrawal and cravings, which can help motivate long-term treatment. confirmedas of 2026-11-07

    12. [12]

      Three medications are approved by the FDA for alcohol use disorder - naltrexone (oral or long-acting injection), acamprosate and disulfiram - and NIAAA says all are nonaddictive and can be used alone or with behavioural treatment or mutual-support groups. confirmedas of 2026-11-07

    13. [13]

      NIDA says fentanyl addiction is a treatable chronic medical condition for which medications are the standard treatment, naming methadone, buprenorphine and naltrexone, with lofexidine approved for withdrawal symptoms. confirmedas of 2025-06-06

      • Fentanyl · National Institute on Drug Abuse · Primary source · How is fentanyl addiction treated? (retrieved 2026-11-07)
      • Fentanyl · National Institute on Drug Abuse · Primary source · How is fentanyl addiction treated? (retrieved 2026-11-07)
    14. [14]

      WHO recommends a range of treatments for opioid dependence and says opioid agonist maintenance treatment with medicines such as methadone and buprenorphine has the strongest evidence of effectiveness and cost-effectiveness; it also lists psychosocial support and antagonist treatment with naltrexone. confirmedas of 2026-11-07

    15. [15]

      NIDA says methadone and buprenorphine can be equally effective at helping people reduce opioid use and both help people stay in treatment, with methadone possibly keeping some people in treatment longer. confirmedas of 2026-11-07

    16. [16]

      NIDA says that when taken as prescribed by a person with opioid use disorder, methadone and buprenorphine do not produce the same high as illegal opioids. confirmedas of 2025-06-06

      • Fentanyl · National Institute on Drug Abuse · Primary source · How is fentanyl addiction treated? (retrieved 2026-11-07)
    17. [17]

      NIDA says medications for opioid use disorder are safe and effective during pregnancy and breastfeeding. confirmedas of 2026-11-07

    18. [18]

      WHO says effective treatments for opioid dependence reduce overdose risk, but fewer than 10% of people worldwide who need such treatment receive it, and only half of countries provide access to effective options. confirmedas of 2026-11-07

    19. [19]

      The 2024 rule also lets opioid treatment programs start buprenorphine through telehealth without an initial in-person physical evaluation, building on flexibilities first allowed during the COVID-19 public health emergency. confirmedas of 2024-02-02

    20. [20]

      NIDA says that since 2020 many people who have been in treatment for a while can receive up to 28 take-home doses of methadone, and that NIDA-funded studies found allowing more take-home doses is safe and may help people stay in treatment. confirmedas of 2026-11-07

    21. [21]

      As of June 2023 there were more than 2,000 opioid treatment programs in the US caring for more than 650,000 patients, according to the 2024 SAMHSA rule. confirmedas of 2024-02-02

    22. [22]

      In February 2025 CDC attributed the fall in overdose deaths to several factors, including wide naloxone distribution, better access to treatment, shifts in the illegal drug supply, the resumption of services after pandemic disruptions and continued investment in prevention programmes. confirmedas of 2025-02-25

    Revision history (1)
    1. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: May 7, 2027.

    Cite this page

    "Opioid use disorder treatment: methadone, buprenorphine, naltrexone." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/opioid-use-disorder-treatment-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.